



Cell-Based Bioassays

in vitro assessment of biological response, potency, expression, and mode of action

Comprehensive
Capabilities

Cutting-edge cGMP-
Compliant Services

Monoclonal
Antibodies (mAbs)

Autologous Therapies
& Tumor Vaccines

solvias 

Comprehensive Capabilities


Solvias has capabilities spanning the entire product lifecycle, from late-stage research, pre-clinical development through commercial release, with particular expertise in **potency, stability, and safety** assessment of biologics and cell & gene therapies.

We understand that cell-based bioassays are unique to each product and our extensive experience allows us to rapidly **develop, transfer, and validate cell-based assays** in compliance with **ICH Q2(R2), ICH Q14, and USP <1033/1210>**.

Bring **your innovation** to its destination

Cutting-edge cGMP-Compliant Services

Our cGMP-compliant services deliver reliable and reproducible results using a broad range of endpoint assessments, including **qPCR, chemiluminescence, absorbance, fluorescence, flow cytometry (FC), capillary electrophoresis, ELISA, LC-MS, and molecular-based techniques**. Our state-of-the-art equipment and in-house cell banks ensure that every assay meets the highest standards, helping you navigate the complexities of drug development with confidence.



Therapeutic, diagnostic and preventive monoclonal antibodies

- Cell binding assays and cytotoxicity assay for a humanized antibody-drug conjugate (ADC)
- Bispecific Abs biopolymer conjugate
- Humanized neutralizing mAbs
- Antagonist blocking mAbs
- Binding assays for Agonist recombinant, humanized, multivalent mAbs
- Binding and competitive assays for myristoylated peptide
- Pentavalent, Bispecific, Trifunctional nanobody
- Immune checkpoint reporter-based bioassays
- Surrogate reporter assays
- Tumor growth/inhibition assays
- Antibody-dependent cellular cytotoxicity (ADCC) assays

Autologous Therapies

Gene therapies

- Hematopoietic progenitor cells for Sickle cell disease (SCD), beta-thalassemia, cerebral adenoleukodystrophy (CALD)
- Colony-forming unit (CFU) assays
 - Potency assay for the specific targeted gene
 - Lentiviral vectors (LVVs)
 - CRISPR-Cas9

Somatic-cell therapies

- CAR-T
- target-specific activation
 - Proliferation
 - Cytotoxicity
 - Safety Cytokine Independent Growth (SCIG)


Tumor Vaccines

Neoantigen-specific immunotherapy

- Personalized mRNA-lipoplex therapeutic cancer vaccines
- Patient-specific mRNA-based

Why partner with us?

- CRO
- Founded in 1999
- 800+ team members
- 175+ PhD-level scientists
- GMP, GLP, ISO9001 certified
- 23K m² of lab capacity
- 700+ customers worldwide
- 5 centers of excellence



Contact us to speak with
an expert: info@solvias.com

  [solvias.com](https://www.solvias.com)

